Floatz logo

Ari-0001

Primary Mediastinal B-cell Lymphoma (PMBCL)

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Primary Mediastinal B-cell Lymphoma (PMBCL) cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Zofran
Miltenyi Biomedicine GmbH
Phase 2BB
Eloxatin
City of Hope Medical Center
Phase 2BB
Bendamustine
Miltenyi Biomedicine GmbH
Phase 2B
Tocilizumab
Jonsson Comprehensive Cancer Center
Phase 1/2CCC

View all 11 →

Same molecule, other indications

Ari-0001 is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Acute Lymphoblastic Leukemia ,LymphomasDormant
B
Indicative ·
60 / 100
View asset →
B-Cell Lymphoma, UnspecifiedDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →